Tumor-Specific D-Dimer Concentration Ranges and Influencing Factors: A Cross-Sectional Study.
D-dimer level in cancer patients is associated with risk of venous thromboembolism and deep venous thrombosis. Most cancer patients have "abnormal" D-dimer levels based on the current normal reference range. To investigate tumor-specific D-dimer reference range, we compared D-dimer levels for nine different tumour types with healthy controls by using simultaneous quantile regression and constructing a median, 5th percentile, and 95th percentile model of normal tumour D-dimer concentration. Associations with tumour primary site, stage, pathological type, and treatment were also explored. Additionally, 190 patients were tracked to reveal the relevance of initial D-dimer levels to cancer prognosis. D-dimer ranges (median, 5th, 95th) in various cancers (mg/L) were: liver 1.12, 0.27, 5.25; pancreatic 0.96, 0.23, 4.81; breast 0.44, 0.2, 2.17; gastric 0.65, 0.22, 5.03; colorectal 0.73, 0.22, 4.45; lung 0.7, 0.25, 4.0; gynaecological 0.61, 0.22, 3.98; oesophageal 0.23, 0.7, 3.45; and head and neck 0.22, 0.44, 2.19. All were significantly higher than that of healthy controls (0.18, 0.07, 0.57). D-dimer peaked 1-2 days postoperatively but had decreased to the normal range by 1 week. Additionally, cancer patients with high initial D-dimer were shown a tendency of poor prognosis in survival rate. In conclusion, D-dimer levels in cancer depend on patient age, tumour primary site, and tumour stage. Thrombosis prevention is necessary if D-dimer has not decreased to the tumor-specific baseline a week after surgery.
The State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, Hubei 430072, China.
Jing
J
Yu
Department of Microbiology, School of Basic Medical Sciences, Wuhan University; Wuhan, China.
Dongqing
D
Li
Department of Laboratory, Hubei Cancer Hospital, Wuhan, China.
Dansheng
D
Lei
Department of Laboratory, Hubei Cancer Hospital, Wuhan, China.
Feng
F
Yuan
Department of Laboratory, Hubei Cancer Hospital, Wuhan, China.
Feng
F
Pei
Department of Laboratory, Hubei Cancer Hospital, Wuhan, China.
Huifeng
H
Zhang
Stago Diagnosis Company, Wuhan, China.
Anming
A
Yu
Department of Laboratory, Hubei Cancer Hospital, Wuhan, China.
Kun
K
Wang
Department of Laboratory, Hubei Cancer Hospital, Wuhan, China.
Hu
H
Chen
Department of Orthopaedics, Renmin Hospital, Wuhan University, Wuhan, China.
Liang
L
Chen
Laboratory of Immunology, University of Lorraine, Lorraine, France.
Xianglei
X
Wu
Department of Laboratory, Hubei Cancer Hospital, Wuhan, China.
Xianli
X
Tong
The State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, Hubei 430072, China.
Yefu
Y
Wang
D000328:Adult; D000367:Age Factors; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009369:Neoplasms / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000401:mortality; D009928:Organ Specificity; D011379:Prognosis; D012016:Reference Values; D015996:Survival Rate; D013997:Time Factors; D054556:Venous Thromboembolism / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000401:mortality; D020246:Venous Thrombosis / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000401:mortality
D000925:Anticoagulants; D005338:Fibrin Fibrinogen Degradation Products; C036309:fibrin fragment D